Quant SARS-CoV-2 Position AESKU.GROUP to nurture collaborations with hospitals and diagnostic labs by highlighting their early implementation of quantitative SARS-CoV-2 antibody tests, suggesting expansion into broader infectious disease serology panels and post-pandemic immune monitoring services.

IVD Innovation Leverage AESKU.DIAGNOSTICS’ strength in innovative in vitro diagnostic products to upsell complementary diagnostic solutions for autoimmune and infectious diseases, including test systems with faster turnaround and improved clinical outcomes.

QC & Autoantibodies Promote AESKU’s AESQC IFA QC product line and AESQC.com portal to labs seeking quality control and standardization for autoantibody testing, offering bundled QC solutions with training and implementation support.

Mid-market Focus Target mid-sized laboratories and regional diagnostics networks (given 51-200 employees) with scalable, cost-effective IVD offerings, services, and support contracts tailored to mid-market volume and service level needs.

Digital & Data Enablement Highlight tech-enabled capabilities such as SAP-based operations, JSON-LD and Piwik analytics to offer integrated supply, inventory, and data insights solutions for customers seeking traceability, compliance, and performance metrics.